If you look at the 'anticipated milestones' on the AGM presentation slides the next is additional validation studies for the Ovarian test in 1H18 (which i can only assume is CY 2018). Further development studies for Lung wont even start until 2H18 by this timeline, and not until after 'technical validation of a standardised autoantibody test' - which is referenced in the 31/10/17 quarterly business update. So my interpretation is no new results on lung until at least the end of 18.
If you look at the 'anticipated milestones' on the AGM...
Add IIQ (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
62.5¢ |
Change
0.050(8.70%) |
Mkt cap ! $65.94M | |||
| Open | High | Low | Value | Volume |
| 57.5¢ | 63.0¢ | 57.5¢ | $117.5K | 196.7K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1000 | 59.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 62.5¢ | 2484 | 2 |
View Market Depth
| Last trade - 16.10pm 05/07/2024 (20 minute delay) ? |
| IIQ (ASX) Chart |